MA58128B1 - Composition de furazidine à libération prolongée - Google Patents
Composition de furazidine à libération prolongéeInfo
- Publication number
- MA58128B1 MA58128B1 MA58128A MA58128A MA58128B1 MA 58128 B1 MA58128 B1 MA 58128B1 MA 58128 A MA58128 A MA 58128A MA 58128 A MA58128 A MA 58128A MA 58128 B1 MA58128 B1 MA 58128B1
- Authority
- MA
- Morocco
- Prior art keywords
- furazidine
- release
- extended
- composition
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne une composition pharmaceutique à libération prolongée de furazidine pour administration orale, qui peut être utilisée pour traiter les infections des voies urinaires (IVU). La composition pharmaceutique à libération prolongée pour administration orale comprend : a) un composant à libération immédiate, comprenant de la furazidine et un ou plusieurs excipients pharmaceutiquement acceptables ; et b) un composant à libération modifiée, comprenant de la furazidine, un agent à libération contrôlée et un ou plusieurs excipients pharmaceutiquement acceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21153203.1A EP4032530B1 (fr) | 2021-01-25 | 2021-01-25 | Composition de furazidine à libération prolongée |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA58128B1 true MA58128B1 (fr) | 2025-05-30 |
Family
ID=74236033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA58128A MA58128B1 (fr) | 2021-01-25 | 2021-01-25 | Composition de furazidine à libération prolongée |
Country Status (15)
| Country | Link |
|---|---|
| EP (2) | EP4032530B1 (fr) |
| DK (1) | DK4032530T3 (fr) |
| ES (1) | ES3030341T3 (fr) |
| FI (1) | FI4032530T3 (fr) |
| HR (1) | HRP20250564T1 (fr) |
| HU (1) | HUE071463T2 (fr) |
| LT (1) | LT4032530T (fr) |
| MA (1) | MA58128B1 (fr) |
| MD (1) | MD4032530T2 (fr) |
| PL (1) | PL4032530T3 (fr) |
| PT (1) | PT4032530T (fr) |
| RS (1) | RS66829B1 (fr) |
| SI (1) | SI4032530T1 (fr) |
| UA (1) | UA130848C2 (fr) |
| WO (1) | WO2022157357A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4545074A1 (fr) | 2023-10-27 | 2025-04-30 | Adamed Pharma S.A. | Composition pharmaceutique de furazidine pour administration vaginale |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2019110218A (ru) * | 2016-10-10 | 2020-11-13 | Фармацевтическое Предприятие Хасцо-Лек С.А. | Новые композиции на основе фуразидина и способы их изготовления |
-
2021
- 2021-01-25 PT PT211532031T patent/PT4032530T/pt unknown
- 2021-01-25 FI FIEP21153203.1T patent/FI4032530T3/fi active
- 2021-01-25 MD MDE20221166T patent/MD4032530T2/ro unknown
- 2021-01-25 LT LTEP21153203.1T patent/LT4032530T/lt unknown
- 2021-01-25 SI SI202130308T patent/SI4032530T1/sl unknown
- 2021-01-25 ES ES21153203T patent/ES3030341T3/es active Active
- 2021-01-25 HU HUE21153203A patent/HUE071463T2/hu unknown
- 2021-01-25 HR HRP20250564TT patent/HRP20250564T1/hr unknown
- 2021-01-25 RS RS20250465A patent/RS66829B1/sr unknown
- 2021-01-25 EP EP21153203.1A patent/EP4032530B1/fr active Active
- 2021-01-25 MA MA58128A patent/MA58128B1/fr unknown
- 2021-01-25 PL PL21153203.1T patent/PL4032530T3/pl unknown
- 2021-01-25 DK DK21153203.1T patent/DK4032530T3/da active
-
2022
- 2022-01-24 WO PCT/EP2022/051486 patent/WO2022157357A1/fr not_active Ceased
- 2022-01-24 EP EP22702430.4A patent/EP4281048A1/fr active Pending
- 2022-01-24 UA UAA202303632A patent/UA130848C2/uk unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022157357A1 (fr) | 2022-07-28 |
| RS66829B1 (sr) | 2025-06-30 |
| UA130848C2 (uk) | 2026-05-27 |
| HRP20250564T1 (hr) | 2025-07-04 |
| EP4281048A1 (fr) | 2023-11-29 |
| FI4032530T3 (fi) | 2025-05-27 |
| MD4032530T2 (ro) | 2025-07-31 |
| HUE071463T2 (hu) | 2025-08-28 |
| EP4032530B1 (fr) | 2025-04-09 |
| ES3030341T3 (en) | 2025-06-27 |
| PT4032530T (pt) | 2025-06-04 |
| EP4032530A1 (fr) | 2022-07-27 |
| LT4032530T (lt) | 2025-05-26 |
| PL4032530T3 (pl) | 2025-06-16 |
| SI4032530T1 (sl) | 2025-06-30 |
| DK4032530T3 (da) | 2025-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46665B1 (fr) | Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y | |
| MA31668B1 (fr) | Polypeptides, domaines variables d'anticorps et antagonistes | |
| MA29744B1 (fr) | Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree | |
| BR0306872A (pt) | Composições e métodos de tratamento envolvendo agonistas do receptor-gama ativado pelo proliferador de peroxissoma e inibidores seletivos da ciclooxigenase-2 | |
| TNSN07424A1 (fr) | Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l'eugenol, le borneol et le carvacrol | |
| MA56748B1 (fr) | Formes à l'état solide de (s)-2-(((s)-6,8-difluoro-1,2,3,4-tétrahydronaphthalén-2-yl)amino)-n-(1-(2-méthyl-1-(néopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide et utilisations assosiées | |
| MA52492B1 (fr) | Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés | |
| MA30359B1 (fr) | Composition pharmaceutique a liberation prolongee sur la base d'un systeme de liberation comprenant un polymere soluble dans l'acide et un polymere dependant du ph | |
| MA29378B1 (fr) | Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer | |
| MA40814A1 (fr) | Compositions pharmaceutiques pour thérapie combinée | |
| Saag et al. | Efficacy and safety of febuxostat extended and immediate release in patients with gout and renal impairment: a phase III placebo‐controlled study | |
| MA29573B1 (fr) | Composition pharmaceutique comprenant un antiviral , un antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol , le thymol, l' eugenol, le borneol et le carvacrol | |
| MA62910A1 (fr) | Inhibiteurs de line-1 pour traiter des maladies du snc et des maladies systémiques | |
| TNSN01170A1 (fr) | Associations d'agonistes de gaba et d'inhibiteurs d'aldose-reductase. | |
| MA27710A1 (fr) | Formulations pharmaceutiques liquides de palonosetrone | |
| MA62992B1 (fr) | Formulations de capsules | |
| MA55027B1 (fr) | Formulations plaisante au goût | |
| MA29907B1 (fr) | Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol, l'eugenol, le thymol, le borneol, le carvacrol et les ionones alpha - et beta- | |
| Mammen-Tobin et al. | Management of metronidazole-resistant Trichomonas vaginalis–a new approach | |
| MX2024009216A (es) | Inhibidores de ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. | |
| MA63248B1 (fr) | Formulations d'un inhibiteur de la kallicréine plasmatique | |
| Evans et al. | A case of stadol dependence | |
| MX2024008330A (es) | Combinacion de obicetrapib e inhibidor de sglt2 | |
| Sand et al. | Efficacy and tolerability of fesoterodine in women with overactive bladder | |
| MX2026000979A (es) | Una forma farmaceutica solida de dosificacion bucodispersable de safinamida |